The 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference will take place in Boston, USA, on November 16–19, 2026. Since 2008, CTAD has served as a global forum dedicated exclusively to Alzheimer’s disease clinical research, bringing together investigators, clinicians, industry scientists, and regulatory experts committed to advancing the field.
CTAD is designed as a focused scientific meeting. All sessions are held in a single main ballroom, ensuring that the entire community shares the same presentations and discussions. This unified format fosters a collective scientific experience, encourages in-depth dialogue, and creates meaningful interactions across disciplines.
The conference offers an opportunity to engage with key opinion leaders, clinical trialists, regulatory representatives, and multidisciplinary research teams, while gaining insight into the latest advances shaping prevention and treatment strategies.
CTAD is also aligned with the Journal of Prevention of Alzheimer’s Disease (JPAD), the conference’s official journal, which extends the reach of the research presented at the meeting to the broader scientific community.
Registration
Register here. Early bird rates until 1 October 2026.
Abstract Submission
Abstracts accepted for presentation at CTAD26 will be published in a supplement of the Journal of Prevention of Alzheimer’s Disease after the event. Submission Deadline: 3 September 2026.
Date and time
Location
Boston, USA